| MP24054 |
| MAPS : OTC Pharmaceuticals: May 2004 |
|
Our price £799 plus VAT |
CLICK
 TO BUY |
This report covers: OTC Pharmaceuticals, over the counter, pharmacy-only medicines, analgesics, pain relievers, cough, cold, sore throat, treatments, gastro-intestinal, products, advertising restrictions, lifted, resale price maintenance, abolished, retail chemists, mail-order, internet, services, licensing regulations, asprin induced asthma, wholesalers, OTC pharmaceutical abuse, Boots, to, expand into, South East Asia,
companies covered include: Bayer, Crookes, Statins, Healthcare, Roche Sells, Vitamins, and Fine Chemical Business, GlaxoSmithKline, Peter Black Direct Marketing, Johnson & Johnson, Novartis, Consumer Health, Pfizer, Reckitt Benckiser, Wyeth
EXECUTIVE SUMMARY
| Executive Summary |
| In 2003, the OTC (over-the-counter) pharmaceuticals market was valued at £1.83bn, which represents an increase of 3.8% on 2002. The rate at which the market was growing decreased in 2002, but this was largely due to the abolition of Resale Price Maintenance (RPM) on OTC pharmaceuticals in 2001, which prompted multiple retailers to offer key, best-selling brands at permanently low prices. |
| OTC pharmaceuticals fall into two broad categories: pharmacy-only (P) products and general sales list (GSL) products. The range of OTC product sectors has grown in line with market trends and as a result of the broadening range of pharmaceuticals that have been approved for sale on an OTC basis. Currently, the main sectors are analgesics (pain relievers), |
| cough/cold/sore throat treatments, skincare treatments and gastro-intestinal products, while other sectors include vitamins and minerals, smoking cessation products, hay fever remedies, eye care treatments, sleeping aids and medicated mouthwashes/sprays. |
| The largest sector, analgesics, has been most markedly affected by |
| price-discounting practices, although this was offset, to some extent, by new product innovations, such as user-friendly methods of drug delivery and products for defined uses/patient groups. |
| Sectors that have seen above-average growth in recent years include smoking cessation products, hay fever remedies and medicated mouthwashes/sprays. Sales in these areas were fuelled by products being reclassified from prescription-only medicines (POMs) to OTC status or from P to GSL status, thereby increasing the availability of these products. |
| Government policies aimed at curbing expenditure on the NHS have sought to promote self-care and the use of OTC pharmaceuticals for self-medication. Recent legislative changes have been designed to speed up the process of reclassification from 'prescription pharmaceutical' to OTC status and to enable a wider range of pharmaceuticals to be made available for retail sale. Prompted by such legislation, pharmaceutical manufacturers are expected to increase their involvement in the OTC sector as they face the expiry of their patents on prescription pharmaceutical brands and the subsequent loss of revenue associated with this. |
| Key Note forecasts limited value growth for this market in the immediate future, reflecting the maturity of many of the sectors and the fact that multiple retailers will continue to keep retail prices low. On a more positive note, there remains significant potential for new brand developments, as products are delisted from P status and as new sectors are developed. |
TABLE OF CONTENTS
| Executive Summary 1 |
| 1. Market Definition 8 |
| REPORT COVERAGE 8 |
| Pharmacy-Only Medicines 8 |
| General Sales List Medicines 8 |
| MARKET SECTORS 8 |
| Analgesics (Pain Relievers) 9 |
| Cough/Cold/Sore Throat Treatments 9 |
| Skincare Treatments 9 |
| Gastro-Intestinal Products 9 |
| Others 10 |
| MARKET TRENDS 10 |
| Consumer Expenditure 10 |
| Table 1: Weekly Household Expenditure on Healthcare |
| and Other Products and Services (£), 2001/2002 10 |
| Government Policy 11 |
| Healthcare Issues 12 |
| ECONOMIC TRENDS 12 |
| Population 12 |
| Table 2: UK Resident Population Estimates by Sex |
| (000), Mid-Years 1999-2003 12 |
| Unemployment 13 |
| Table 3: Actual Number of Unemployed |
| Persons in the UK (million), 1999-2003 13 |
| Household Disposable Income 13 |
| Table 4: Average Annual UK Household Disposable Income |
| (£), 1998-2002 14 |
| MARKET POSITION 14 |
| The UK 14 |
| Table 5: Expenditure on NHS Pharmaceuticals |
| and as a Percentage of Total NHS Expenditure |
| (£m at msp and %), 1998-2002 15 |
| Overseas 15 |
| Table 6: Average Annual Expenditure Per Person on |
| Pharmaceuticals in the US, Japan and Europe |
| by Country (£), 2002 16 |
| Table 7: Expenditure on Pharmaceuticals as a Proportion |
| of GDP in the US, Japan and Europe by Country (%), 2002 17 |
| 2. Market Size 18 |
| THE TOTAL MARKET 18 |
| Table 8: The Total UK Market for OTC Pharmaceuticals |
| by Sector by Value at Current Prices (£m at rsp), 1999-2003 18 |
| BY MARKET SECTOR 19 |
| Analgesics 19 |
| Table 9: The UK OTC Analgesics Sector by Value |
| at Current Prices (£m at rsp and %), 1999-2003 20 |
| Cough/Cold/Sore Throat Treatments 20 |
| Table 10: The UK OTC Cough/Cold/Sore Throat Treatments Sector by Value at Current Prices (£m at rsp and %), 1999-2003 21 |
| Skincare Treatments 21 |
| Table 11: The UK OTC Skincare Treatments Sector by Value |
| at Current Prices (£m at rsp and %), 1999-2003 22 |
| Gastro-Intestinal Products 23 |
| Table 12: The UK OTC Gastro-Intestinal Products Sector |
| by Value at Current Prices (£m at rsp and %), 1999-2003 23 |
| Other OTC Products 24 |
| Table 13: The UK Other OTC Products Sector by Value |
| at Current Prices (£m at rsp and %), 1999-2003 24 |
| OVERSEAS TRADE 25 |
| Table 14: UK Overseas Trade in Pharmaceuticals (£m), 2002 25 |
| 3. Industry Background 26 |
| RECENT HISTORY 26 |
| Delisting 26 |
| Changes in Delisting Procedures 27 |
| Abolition of Resale Price Maintenance 27 |
| Advertising Restrictions Lifted 28 |
| Royal Pharmaceutical Society of Great Britain Code of Ethics 28 |
| Prescription Charges 28 |
| Government Reforms to Pharmacy Regulations 29 |
| INDUSTRY SYNOPSIS 29 |
| Table 15: Average Financial Results for Manufacturers of |
| Pharmaceutical Preparations (£000, % and £), 2004 30 |
| NUMBER OF COMPANIES 30 |
| Table 16: Number of UK VAT-Based Enterprises Engaged |
| in the Manufacture of Pharmaceutical Preparations |
| by Turnover Sizeband, 2003 31 |
| EMPLOYMENT 31 |
| REGIONAL VARIATIONS IN THE MARKETPLACE 31 |
| DISTRIBUTION 32 |
| Retail Chemists 32 |
| Table 17: Community Pharmacies in Great Britain by Type (number and %), May 2003 32 |
| Wholesalers 33 |
| Mail-Order and Internet Services 33 |
| HOW ROBUST IS THE MARKET? 33 |
| LEGISLATION 34 |
| The Selected List 34 |
| Licensing Regulations 34 |
| Advertising Regulations 35 |
| European Agency for the Evaluation of Medicinal Products 36 |
| KEY TRADE ASSOCIATIONS 36 |
| Association of the British Pharmaceutical Industry 36 |
| Association of the European Self-Medication Industry 36 |
| National Pharmaceutical Association 36 |
| Proprietary Association of Great Britain 37 |
| Royal Pharmaceutical Society of Great Britain 37 |
| 4. Competitor Analysis 38 |
| THE MARKETPLACE 38 |
| MARKET LEADERS 38 |
| Bayer PLC 38 |
| Company Structure 38 |
| Current and Future Developments 39 |
| Financial Results 39 |
| Crookes Healthcare Ltd 39 |
| Company Structure 39 |
| Current and Future Devlopments 39 |
| Financial Results 40 |
| GlaxoSmithKline PLC 40 |
| Company Structure 40 |
| Current and Future Developments 40 |
| Financial Results 41 |
| Johnson & Johnson Ltd 41 |
| Company Structure 41 |
| Current and Future Developments 41 |
| Financial Results 41 |
| Novartis Consumer Health UK Ltd 41 |
| Company Structure 41 |
| Current and Future Developments 42 |
| Financial Results 42 |
| Pfizer Ltd 42 |
| Company Structure 42 |
| Current and Future Developments 43 |
| Financial Results 43 |
| Reckitt Benckiser PLC 43 |
| Company Structure 43 |
| Current and Future Developments 43 |
| Financial Results 43 |
| Wyeth Consumer Healthcare 44 |
| Company Structure 44 |
| Current and Future Developments 44 |
| Financial Results 44 |
| OUTSIDE SUPPLIERS 44 |
| Table 18: UK Expenditure on Pharmaceutical Research |
| and Development (£m and %), 1998-2002 45 |
| MARKETING ACTIVITY 45 |
| Main Media Advertising 45 |
| Table 19: Main Media Advertising Expenditure |
| on OTC Pharmaceuticals by Product Sector (£000), |
| Years Ending September 2002 and 2003 46 |
| Table 20: Main Media Advertising Expenditure |
| on Pharmaceuticals by Type of Product by Brand |
| (£000), Year Ending September 2003 47 |
| 5. Strengths, Weaknesses, Opportunities and Threats 52 |
| STRENGTHS 52 |
| WEAKNESSES 53 |
| OPPORTUNITIES 53 |
| THREATS 54 |
| 6. Buying Behaviour 55 |
| INTRODUCTION 55 |
| MEDICAL CONDITIONS 55 |
| Table 21: Incidence of Common Medical Conditions |
| in the Previous 12 Months (% of adults), March 2003 56 |
| OTC PRODUCT USAGE 57 |
| Table 22: Consumer Usage of OTC Pharmaceuticals by Type |
| During the Previous 12 Months (% of adults), March 2003 57 |
| PURCHASING OF OTC PHARMACEUTICALS BY TYPE |
| OF OUTLET 58 |
| Table 23: Consumer Purchase of OTC Pharmaceuticals |
| by Type of Outlet (% of adults), 2003 58 |
| 7. Current Issues 59 |
| NEW ADVERTISING GUIDANCE 59 |
| REPORT ON ASPIRIN-INDUCED ASTHMA 59 |
| OTC PHARMACEUTICAL ABUSE 59 |
| CORPORATE ACTIVITY 60 |
| Roche Sells Vitamins and Fine Chemicals Business 60 |
| Interest Shown in Roche Consumer Healthcare Business 60 |
| Peter Black Direct Marketing Acquired 60 |
| LEGISLATIVE CHANGES 60 |
| Proposal to Delist Statins to OTC Status 60 |
| ADVERTISING AND PROMOTION 61 |
| 8. The Global Market 62 |
| LEADING GLOBAL MARKETS 62 |
| Table 24: Balance of Trade in Pharmaceuticals |
| by Country (£m), 2002 62 |
| LEADING GLOBAL PLAYERS 63 |
| Table 25: Top Ten Leading Players in the Global Pharmaceuticals Market by Sales and Global Market Share |
| (£m and %), 2001 63 |
| MAJOR TRENDS 64 |
| The Internet 64 |
| Per Capita Spending on Pharmaceuticals 64 |
| Table 26: Annual Per Capita Expenditure on Pharmaceuticals |
| by Country (£), 2002 65 |
| Expenditure on Pharmaceuticals as a Proportion of GDP 65 |
| THE FUTURE 65 |
| 9. Forecasts 67 |
| INTRODUCTION 67 |
| Attitudes Towards Healthcare 67 |
| The Ageing Population 67 |
| Reclassification of Pharmaceuticals 67 |
| FORECASTS 2004 TO 2008 67 |
| Table 27: The Forecast Total UK Market for OTC |
| Pharmaceuticals by Value at Current Prices |
| (£m at rsp), 2004-2008 68 |
| FUTURE TRENDS 68 |
| Deregulation of the Pharmacy Market 68 |
| Internet and Mail-Order Distribution 68 |
| Boots to Expand in South East Asia 68 |
| Product Development 69 |
| A Vision for Pharmacy in the New NHS 69 |
| 10. Company Profiles 70 |
| Crookes Healthcare Ltd 71 |
| Glaxosmithkline Plc 73 |
| Johnson & Johnson Ltd 75 |
| Novartis Consumer Health Uk Ltd 77 |
| Pfizer Ltd 79 |
| Reckitt Benckiser Plc 81 |
| 11. Further Sources 83 |
| Associations 83 |
| Publications 84 |
| General Sources 84 |
| Government Sources 85 |
| Other Sources 86 |
| Bonnier Information Sources 86 |
Text © 2004 Key Note
| Can't find what you
need? Try our "Research on Request" market report service and define your own report research! Fixed prices - £150, £450 and £1,250 - and fixed delivery of 4, 5 and 14 days |
| Click here for full details |
Ariadne - working together with our customers
to enhance productivity and increase knowledge
© 2004
www.the-list.co.uk Ariadne
Last updated by Amanda Porteous September
2004
